JOURNAL DE MYCOLOGIE MEDICALE is a premier publication in the field of infectious diseases, particularly focusing on the study of mycology and its clinical implications. Published by MASSON EDITEUR, this esteemed journal is based in France and has been disseminating valuable research since its inception in 1994. With an ISSN of 1156-5233 and an E-ISSN of 1773-0449, it plays a critical role in advancing knowledge in mycological infections, positioning itself in the Q3 category for infectious diseases as per the 2023 quartiles. As indicated by its ranking in Scopus, ranking #142 out of 344 in the medicine-infectious diseases category, the journal maintains a prominent presence within the academic community, appealing to researchers, healthcare professionals, and students alike. Although access options are not open access, the journal endeavors to promote a deeper understanding of mycological studies that are crucial for combating ongoing and emerging infectious threats. As it continues to converge on new findings up to 2024, JOURNAL DE MYCOLOGIE MEDICALE remains an essential resource for those invested in the critical intersections of mycology and medicine.

ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA is a distinguished academic journal published by AKADEMIAI KIADO ZRT, focusing on significant advancements in the fields of microbiology, immunology, and infectious diseases. Established in 1994, this journal serves as a vital platform for researchers, professionals, and students keen on exploring the complexities of microbial interactions and immune responses. With a current Impact Factor reflecting its rank within the Q3 categories for Immunology, Microbiology, and Infectious Diseases, it retains a critical position in disseminating innovative research. Although not open access, the journal provides extensive insights disseminated through various academic databases, ensuring a broad reach within the scholarly community. Its convergence over three decades indicates a robust commitment to excellence in scientific inquiry and knowledge sharing. As it moves towards the future, ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA continues to uphold its legacy of fostering collaborative research initiatives that contribute to the understanding and treatment of microbial diseases globally.

CLINICAL MICROBIOLOGY AND INFECTION is a leading journal published by Elsevier Science Ltd, dedicated to advancing the field of infectious diseases and clinical microbiology. With its ISSN 1198-743X and E-ISSN 1469-0691, this esteemed journal has maintained its influential presence since 1995, showcasing high-impact research that addresses critical issues in the diagnosis, treatment, and prevention of infections. Ranked in the Q1 quartile for Infectious Diseases, Medicine (miscellaneous), and Microbiology (medical) categories, and boasting impressive Scopus rankings of #12 and #7 respectively, it sits at the forefront of scientific inquiry in these disciplines. Although it is not an Open Access journal, it provides comprehensive access options for institutions and individuals, ensuring the dissemination of vital research findings. As the field of clinical microbiology continues to evolve, CLINICAL MICROBIOLOGY AND INFECTION remains an essential resource for researchers, clinicians, and students aiming to stay informed on the latest developments and breakthroughs in understanding infectious diseases.

JOURNAL OF INFECTION AND CHEMOTHERAPY, published by Elsevier, is a leading journal in the fields of Infectious Diseases, Microbiology, and Pharmacology. With a solid reputation reflected in its prestigious Q2 ranking in Infectious Diseases and Pharmacology, and Q3 in Microbiology (medical), this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements in the diagnosis, treatment, and prevention of infectious diseases. The journal provides a platform for high-quality, peer-reviewed scholarly articles, making it an essential reference point in the medical community. Despite being published without open access, it continues to attract significant scholarly attention, as denoted by its rankings in Scopus, which showcases its impact within the academic landscape. With a timeline converging from 1995 to 2024, JOURNAL OF INFECTION AND CHEMOTHERAPY is dedicated to advancing knowledge and contributing to better health outcomes globally.

CLINICAL MICROBIOLOGY REVIEWS, published by the American Society for Microbiology, is a leading journal in the fields of epidemiology, immunology, and microbiology, notably recognized for its Q1 status in multiple categories such as Infectious Diseases and Public Health. With an ISSN of 0893-8512 and E-ISSN of 1098-6618, this esteemed journal offers comprehensive reviews and analyses that contribute to the advancement of clinical microbiology practices worldwide. Since its inception in 1988, it has established itself as a pivotal resource for researchers and healthcare professionals, delivering high-quality, peer-reviewed articles that are instrumental in understanding microbial diseases. The journal is highly regarded in the academic community, boasting impressive Scopus rankings, including Rank #1 in Medical Microbiology and a commendable 99th percentile in Public Health. Although not available as an open-access publication, CLINICAL MICROBIOLOGY REVIEWS remains an essential tool for those seeking to enhance their knowledge and practice in microbiology, making significant impacts on clinical outcomes and public health initiatives.

Current Treatment Options in Infectious Diseases, published by SpringerNature, is a pivotal peer-reviewed journal dedicated to advancing the field of infectious disease management and therapy. With a focus on the latest treatment modalities, this journal serves as a vital resource for researchers, healthcare professionals, and students striving to improve patient outcomes in infectious diseases. Although it is not an open-access journal, it offers valuable insights through carefully curated articles that emphasize evidence-based practices and innovative approaches in the treatment landscape. By fostering a cross-disciplinary dialogue, Current Treatment Options in Infectious Diseases aims to bridge the gap between research and clinical application, making it an essential platform for staying abreast of developments in this rapidly evolving field.

MICROBIAL PATHOGENESIS, published by Academic Press Ltd - Elsevier Science Ltd, is a prominent journal in the fields of Infectious Diseases and Microbiology, with a notable impact factor and classified in the Q2 quartile for both categories as of 2023. Since its inception in 1986, this journal has provided a platform for the dissemination of cutting-edge research that enhances our understanding of microbial infections and their implications in health and disease. The journal is indexed in Scopus, ranking #80 among 344 in Infectious Diseases and #57 among 182 in Microbiology, underscoring its significant contribution to the scientific community. Although it operates under a traditional subscription model, the content is vital for researchers, professionals, and students focused on the dynamics of microbial pathogenesis and the development of innovative therapeutic strategies. The journal's comprehensive scope aims to foster advancements in this critical area of study, bridging the gap between laboratory research and clinical applications.

MICROBES AND INFECTION is a premier academic journal published by Elsevier, dedicated to the dynamic fields of immunology, infectious diseases, and microbiology. With a notable impact factor reflective of its high-quality research contributions, the journal is categorized in the Q2 quartile across these fields as of 2023. Based in France and operating since 1999, MICROBES AND INFECTION offers a platform for researchers, professionals, and students to disseminate and access cutting-edge findings that drive innovation and knowledge in microbial and infectious disease research. The journal is ranked impressively within the Scopus database, securing ranks such as #16 in Microbiology and #33 in Infectious Diseases, underscoring its high relevance in the scientific community. Subscribers to the journal can expect an array of articles, reviews, and original research, all designed to advance understanding and improve clinical practices in the fight against infectious agents. With its ongoing commitment to open access options, MICROBES AND INFECTION continues to foster global collaboration and information sharing in the pursuit of addressing pressing microbiological challenges.

Welcome to the International Journal of Medical Microbiology, a leading publication in the field of microbiological research and infectious diseases, offered by Elsevier GmbH. Established in 2000, this esteemed journal provides a scholarly platform for the presentation of high-quality research, reviews, and innovations that bridge medical microbiology and clinical applications. With an impressive impact factor positioning it within the Q1 category across multiple disciplines, including Infectious Diseases, Microbiology, and Medicine, the journal is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of microbial pathogenesis, diagnostics, and therapeutics. The International Journal of Medical Microbiology is committed to open access, promoting the dissemination of knowledge and accessibility for researchers, professionals, and students worldwide. Based in Munich, Germany, the journal continues to play a vital role in the global scientific community, fostering collaborations and inspiring future innovations in the fight against infectious diseases.

Infectious Diseases, published by TAYLOR & FRANCIS LTD, is a leading academic journal dedicated to advancing research in the field of infectious diseases and microbiology. With an impressive impact factor and categorized in Q1 in multiple areas including Immunology and Microbiology, this journal serves as a critical platform for researchers, practitioners, and students to disseminate their findings and stay abreast of current advancements. The journal is recognized for its rigorous peer-review process and aims to foster innovation and collaboration across disciplines from 2015 to 2024. It boasts a robust Scopus ranking, positioning it favorably among the top-tier of journals in the relevant fields, making it an essential resource for anyone involved in infectious disease research. Access options are available, ensuring that the latest research is accessible to a global audience, thus emphasizing the journal's commitment to promoting knowledge and understanding in the ever-evolving landscape of infectious diseases.